Health
Lilly's ads can continue after Novo challenge, judge rules
Novo Nordisk has suffered another setback in its uphill battle against Eli Lilly in the booming obesity drug market after a US judge rejected its attempt to block television ads that Novo alleges are misleading. ...
- Published
- (1 h ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 36-word snippet. The full article is at the source.
More from Endpoints News and around the same time
Draft COINS rules could threaten broad China collaborationsThe release of draft regulations from the Treasury Department has spurred an intense debate over the future of China biotech deals, which could be sharply curtailed under the proposal as written. The draft bars US ...Gubra looks beyond metabolism, hopes for first portfolio company this yearThe Copenhagen-based drugmaker Gubra's present is mostly about obesity. Its future will need to be about a much broader pipeline. The company has a portfolio of weight loss drug candidates but is moving into the ...Artiva to wind down after two patient deaths in autoimmune cell therapy trialsCell therapy biotech Artiva Biotherapeutics abruptly announced Tuesday morning that it is effectively shutting down and laying off almost all of its staff after two patients died in its clinical trials. Researchers had been…Outpace ends an ovarian cancer trial; Incyte data impresses at ESMOPlus news about Genmab, Rumi, Prana and Fractyl. Outpace Bio ends cell therapy trial: The Seattle startup canned a Phase 1 ovarian cancer trial of its mesothelin autologous CAR-T, called OPB-101 ...After Makary's FDA exit, biopharma exhales: Signal SurveyWhen Endpoints Signal released the Q3 Biopharma Sentiment Index last week, it showed a level of industry optimism not seen in years. Behind the topline figure, one area of improvement really stood ...Ferring to acquire ovary-in-a-dish startup Gameto for up to $1.38BFerring Pharmaceuticals has signed an agreement to acquire the fertility startup Gameto in a deal that could be worth up to $1.3825 billion, the companies told Endpoints News ahead of aThis page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
